A Randomized, Open-label Study to Assess the Safety and Tolerability of Multiple Dose Levels and Multiple Dosing Regimens of AT2101 in Adult Patients With Type 1 Gaucher Disease Currently Receiving ERT.

Trial Profile

A Randomized, Open-label Study to Assess the Safety and Tolerability of Multiple Dose Levels and Multiple Dosing Regimens of AT2101 in Adult Patients With Type 1 Gaucher Disease Currently Receiving ERT.

Completed
Phase of Trial: Phase II

Latest Information Update: 20 May 2014

At a glance

  • Drugs Isofagomine tartrate (Primary)
  • Indications Gaucher's disease type I
  • Focus Adverse reactions
  • Sponsors Amicus Therapeutics
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 20 May 2014 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top